CTLA4 and neoplasm: When CTLA-4/B7 interactions are blocked by injection of anti-CTLA-4 monoclonal antibody during cancer vaccination, therapeutic T-cell immunity against even poorly immunogenic tumours such as B16 melanoma can be eliminated [14].